Table 1. Demographic and clinical characteristics of IBD patients in the control group and the single-session treatment group.
| Control group (n = 12) | Single-session treatment group (n = 33) | |
|---|---|---|
| Sex (M/F) | 8/4 | 16/17 |
| Age (years, mean±SD) | 45.8±15.2 | 40.1±12.8 |
| Weight (kg, mean±SD) | 65.5±10.2 | 65.7±12.9 |
| Crohn´s disease/ulcerative colitis | 8/4 | 27/6 |
| Iron deficiency/ iron-restricted anemia | 8/4 | 13/20 |
| Ferric carboxymaltose dose (500mg/1000mg) | 8/4 | 13/20 |
| Infliximab dose | 5 mg/kg | 5 mg/kg |
| Number of visits to GI outpatient clinic for IV treatment administration (IFX, FCM) | 2 | 1 |
| Infliximab patient (naïve/pretreated) | 2/10 | 8/25 |
| Years of IBD diagnosis (mean±SD) | 7.8±9.2 | 12.5±10.5 |
| Active IBD * (Y/N) pre-FCM | 11/1 | 28/5 |
| Active IBD * (Y/N) post-FCM | 9/3 | 20/13 |
| Mean CRP (pre-FCM/post-FCM) | 10.1/14.6 | 18.4/8.6 |
| Treatment successful ** (Y/N) | 8/4 | 26/7 |
| Adverse Drug Reactions | None | None |
(**) Successful treatment was defined for iron-restricted anemia as Hb increase ≥2 g/dL or Hb normalization (Hb >12 g/dL in female, Hb >13 g/dL in male patients), and for iron deficiency as TSAT normalization (TSAT >20%) and/or s-ferritin >100 μg/L, over the 8-week study period.